Search Results - "Taskinen, Marja-Riitta"

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Role of endogenous incretins in the regulation of postprandial lipoprotein metabolism.

Authors: Taskinen, Marja-Riitta Matikainen, Niina Björnson, Elias et al.

Source: European Journal of Endocrinology. Jul2022, Vol. 187 Issue 1, p75-84. 10p.

Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes.

Authors: Taskinen, Marja‐Riitta Björnson, Elias Matikainen, Niina et al.

Source: Diabetes, Obesity & Metabolism. May2021, Vol. 23 Issue 5, p1191-1201. 11p.

Lipids and lipoproteins as coronary risk factors in non-insulin-dependent diabetes mellitus.

Authors: Syvanne, Mikko Taskinen, Marja-Riitta

Source: Lancet. 7/20/1997, Vol. 350 Issue 9072, pSI20. 4p. 1 Diagram.

Subjects: Dyslipidemia, Type 2 diabetes, Diabetic angiopathies, Prevention

Role of apolipoprotein C‐III overproduction in diabetic dyslipidaemia.

Authors: Adiels, Martin Taskinen, Marja‐Riitta Björnson, Elias et al.

Source: Diabetes, Obesity & Metabolism. Aug2019, Vol. 21 Issue 8, p1861-1870. 10p.

Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome.

Authors: Lim, Soo Taskinen, Marja‐Riitta Borén, Jan

Source: Obesity Reviews. Apr2019, Vol. 20 Issue 4, p599-611. 13p. 1 Diagram, 4 Charts.

Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.

Authors: Taskinen, Marja-Riitta Del Prato, Stefano Bujas-Bobanovic, Maja et al.

Source: Atherosclerosis (00219150). Sep2018, Vol. 276, p124-130. 7p.

This result is not displayed to guests.
Login for full access.

New insights into the pathophysiology of dyslipidemia in type 2 diabetes.

Authors: Taskinen, Marja-Riitta Borén, Jan

Source: Atherosclerosis (00219150). Apr2015, Vol. 239 Issue 2, p483-495. 13p.

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial.

Authors: Roth, Eli M. Taskinen, Marja-Riitta Ginsberg, Henry N. et al.

Source: International Journal of Cardiology. Sep2014, Vol. 176 Issue 1, p55-61. 7p.

Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials.

Authors: Del Prato, Stefano Taskinen, Marja-Riitta Owens, David R et al.

Source: Journal of Diabetes & its Complications. 2013 May-Jun, Vol. 27 Issue 3, p274-279. 6p.

This result is not displayed to guests.
Login for full access.

Statins are diabetogenic – Myth or reality?

Authors: Sattar, Naveed Taskinen, Marja-Riitta

Source: Atherosclerosis (Supplements). Aug2012, Vol. 13 Issue 1, p1-10. 10p.

Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat.

Authors: Matikainen, Niina Taskinen, Marja-Riitta Stennabb, Sanna et al.

Source: European Journal of Endocrinology. Mar2012, Vol. 166 Issue 3, p487-492. 6p. 4 Charts, 2 Graphs.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

LDL-cholesterol, HDL-cholesterol or triglycerides—which is the culprit?

Authors: Taskinen, Marja-Riitta¹ mataskin@helsinki.fi

Source: Diabetes Research & Clinical Practice. Jul2003 Supplement, Vol. 61, pS19-S26. 8p.

Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without type 1 diabetes.

Authors: Colhoun, Helen M. Taskinen, Marja-Riitta Otvos, James D. et al.

Source: Diabetes. Nov2002, Vol. 51 Issue 11, p3300-3305. 6p. 3 Charts.